Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer

Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer The Tecentriq combination improved overall survival and progression-free survival compared with sorafenib in people with unresectable HCC Approval by the China National Medical Products Administration brings... Read more

MKS Instruments Declares Quarterly Cash Dividend

ANDOVER, Mass. , Oct. 27, 2020 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of technologies that enable advanced processes and improve productivity, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.20 per share, payable on Read more

GE Healthcare Introduces Serena Bright, Industry’s First Contrast-Enhanced Guided Biopsy Solution

CHICAGO, IL – OCTOBER 20, 2020 – GE Healthcare today announced the availability of Serena Bright™ in the United States.  Serena Bright™ is the industry’s first contrast-enhanced guided biopsy solution and will help empower clinicians and patients in their fight against breast cancer. Receiving U.S. Food and Drug Administration 510(k) clearance in June, this technology... Read more

Children’s Mercy Kansas City Teams Up with Pacific Biosciences to Fight Rare Disease

KANSAS CITY, Mo., and MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) — Children’s Mercy Kansas City, one of the nation’s top pediatric medical systems, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a collaboration designed to further understand the most challenging pediatric... Read more

First nine months of the year with 1% sales growth at constant exchange rates, significant impact of COVID-19 pandemic

Basel, 15 October 2020 Group sales increase 1%1 at constant exchange rates and decline 5% in Swiss francs as a result of continued appreciation of the Swiss franc against most currencies Impact of COVID-19 pandemic: Following strong sales growth in the first quarter (+7%) and COVID-19 related decline in the second quarter (-4%) sales stabilise... Read more

Roche to launch laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients

Basel, 13 October 2020 The Elecsys® SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection This new solution will run on all Roche cobas e immunochemistry analysers which are widely available around the world, thus helping to increase testing capacity In combination with other COVID-19 diagnostic... Read more

Imaging Cilia and Centrioles Below the Diffraction Limit

Novel use of expansion microscopy with ZEISS Airyscan technology Primary cilia are organelles that protrude from the cell surface and function as “cellular antennae” to receive and transduce extracellular signals. They are approximately 3 µm in length and 0.3 µm in diameter, which is below the optical diffraction limit of standard light microscopes. Junior Associate... Read more

Applying Connectomics to Retinal Disease

Research highlights use of ZEISS MultiSEM and ZEISS Sigma electron microscopes Globally, macular degeneration of the retina is a leading cause of legal blindness; however, little is known about its cause. A recent article by Dr. Charles Zucker, Staff Scientist at Harvard University, and colleagues describes electron microscopic observations from the retina of a woman... Read more

The following press release is in German language only – QIAGEN investiert mehr als 110 Mio. Euro in die Erhöhung der Produktions-kapazitäten für Coronavirus-Tests

Hilden, 8. September 2020 – QIAGEN hat heute angekündigt, mehr als 110 Mio. Euro in den Ausbau seiner Kapazitäten für die Fertigung von COVID-19-Testprodukten an den Standorten Hilden, Germantown (Maryland, USA) und Barcelona zu investieren. Mit dem bislang größten Investitionsprogramm in der Unternehmensgeschichte setzt QIAGEN seine Anstrengungen fort, den globalen Kampf gegen die Pandemie durch die Erhöhung von... Read more